Source item
Open original source ↗this. US slower and more expensive than even Europe, where the distributed (part-private) reviewer network gives Europe them more aggregate capacity than FDA
Quoted context
These are the quoted author’s words.
the bio vs AI debate over curing disease in the next 5-10 years seems to revolve around data vs intelligence obviously we need both? but the bottleneck is actually regulatory - we need fast and cheap clinical trials in the US, not just China and Australia
pdhsu ↗